RecruitingAtrial Fibrillation (AF)Persistant Atrial Fibrillation
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Eligible age
18+ yrs
Accepts
All genders
Locations
20 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).
Sponsor: Boston Scientific Corporation
You may qualify if…
- ✓ 1. ≥ 18 years of age, or older if required by local law
- ✓ 2. Have symptomatic drug-refractory1, persistent AF2, confirmed by both:
- ✓ Documentation, such as physician note, of persistent continuous AF for \> 7 days and ≤ 365 days and the arrhythmia symptoms
- ✓ Documentation, within 180 days of enrollment date of either:
- ✓ A 24-hour continuous ECG recording confirming continuous AF or
- ✓ Two (2) ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days apart
- ✓ 3. Willing and capable of providing informed consent
- ✓ 4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center
You may not qualify if…
- ✕ 1. Any of the following atrial conditions:
- ✕ 1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if1 LA diameter not available, non-indexed volume \>100 ml (physician note or imaging)
- ✕ 2. Any prior left atrial ablation
- ✕ 3. Any prior atrial surgery
- ✕ 4. Current atrial myxoma
- ✕ 5. Current left atrial thrombus
- ✕ 6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
- ✕ 2. Any of the following cardiovascular conditions:
Where it's recruiting
Source: ClinicalTrials.gov · NCT07187115 · last updated 2026-05-28